Physician profile
Amy Rojo
NPI 1619661899
$1,180.75
in general payments reported to CMS, 2019-2025
10 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $162 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $323.48 | 2024-2025 | Precision7, Precision 1, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $257.94 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $180.74 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $103.01 | 2025 | |
| Dompe US, INC. | $77.21 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $69.19 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $63.69 | 2025 | Xiidra, Miebo, Biotrue One Day |
| Oyster Point Pharma, INC. | $53.95 | 2024-2025 | Tyrvaya |
| Coopervision INC. | $37.33 | 2025 | Clariti Contact Lens, Myday Contact Lens |
| Biotissue Holdings INC. | $14.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.